MiR 221/222 as new players in tamoxifen resistance

Current Pharmaceutical Design

Volumn 22, Issue 46, 2016, Pages 6946-6955

  Alamolhodaei, Nafiseh Sadat ^a   Behravan, Javad ^a   Mosaffa, Fatemeh ^a   Karimi, Gholamreza ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; MicroRNAs; MiR 221 222; Multidrug resistance; Tamoxifen resistance

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; ESTROGEN RECEPTOR ALPHA; MICRORNA 221; MICRORNA 222; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PUMA PROTEIN; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR FKHRL1; TUMOR MARKER; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MICRORNA;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE REGULATION; DNA REPAIR; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVITY; EXOSOME; GENE TARGETING; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; METABOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICRORNAS; TAMOXIFEN;

EID: 85012054820     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666161102100211     Document Type: Review

References (119)

1. Rutnam ZJ, Wight TN, Yang BB. miRNAs regulate expression and function of extracellular matrix molecules. Matrix Biol 2012; 32: 74-85
2. Esquela-Kerscher A, Slack FJ. Oncomirs microRNAs with a role in cancer. Nat Rev Cancer 2006; 6(4): 259-69
3. Lee RC, Feinbaum, RL, Ambros V. The C. elegansheterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-54
4. Hinske L. A potential role for intragenic miRNAs on their hosts’ interactome. BMC Genomics 2010; 11: 533
5. Sarkar F H, Li Y, Wang Z, Kong D, Ali sh. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010; 13(3): 57-66
6. Sempere LF, Christensen M, Silahtaroglu A, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007; 67(24): 11612-20
7. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23: 4051-60
8. Rutnam ZJ, Wight TN, Yang BB. miRNAs regulate expression and function of extracellular matrix molecules. Matrix Biol 2012; 32: 74-85
9. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931-4
10. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs are the answers in sight?. Nat Rev Genet 2008; 9: 102-14
11. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-89
12. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33
13. Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009; 23(18): 2152-165
14. Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther 2008; 7(12): 3655-60
15. Baker M. RNA interference: microRNAs as biomarkers. Nature 2010; 464: 1227
16. Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19 (1): 92-105
17. Serpico D, Molino L, Di Cosimo S. microRNAs in breast cancer development and treatment. Cancer Treat Rev 2014; 40(5): 595-604
18. Dvinge H, Git A, Graf S, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013; 497: 378-82
19. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893-917
20. Goh JN, Loo SY, Datta A, et al. microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer. Biol Rev Camb Philos Soc 2016; 91(2): 409-28
21. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275-92
22. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24(14): 2137-50
23. Curigliano G, Rigo R, Colleoni M. Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. Clin Breast Cancer 2004; 5: 125-130
24. Janssen EA, Slewa A, Gudlaugsson E, et al. Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol 2010; 23(12): 1567-76
25. Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008; 26: 3153-8
26. Stingl J. Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer 2011; 2: 85-90
27. Singh R, Mo YY. Role of microRNAs in breast cancer. Cancer Biol Ther 2013; 14: 201-12
28. Blamey RW. Guidelines on endocrine therapy of breast cancer EUSOMA. Eur J Cancer 2002; 38: 615-34
29. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310(3): 1062-75
30. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988; 48: 812-5
31. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009; 361: 766-76
32. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9(9): 631-43
33. Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol 2005; 239: 27-36
34. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvanttamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-84
35. NwaboKamdje AH, SekeEtet PF, Vecchio L, et al. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal 2014; 26: 2843-56
36. Pan YZ, Morris M E, Yu AM. MicroRNA-328 negatively regulates theexpression of breast cancer resistance protein (BCRP/ABCG2) in human cancercells. Mol Pharmacol 2009; 6: 1374-9
37. Lyng MB, Lænkholm AV, Søkilde R, Gravgaard KH, Litman T, Ditzel HJ. Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen monotherapy: a DBCG study. PloS One 2012; 7(5): e36170
38. Kalalinia F, Elahian F, Mosaffa F, Behravan J. Celecoxib up regulates the expression of drug efflux transporter ABCG2 in breast cancer cell lines. Iran J Pharm Res 2013; 13(4): 1393-401
39. Rueff J, Rodrigues AS. Cancer Drug Resistance: A brief overview from a genetic viewpoint. Methods Mol Biol 2016; 1395: 1-18
40. Malekshah OM, Bahrami AR, Afshari JT, Mosaffa F, Behravan J. Correlation between PXR and ABCG2 patterns of mRNA expression in a MCF7 breast carcinoma cell derivative upon induction by proinflammatory cytokines. DNA Cell Biol 2011; 30(1): 25-31
41. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970; 30: 1174-84
42. Garofalo M, Croce CM. MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat 2013; 16 (3): 47-59
43. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010; 10: 147-56
44. Mosaffa F, Kalalinia F, Parhiz BH, Behravan J. Tumor necrosis factor alpha induces stronger cytotoxicity in ABCG2overexpressing resistant breast cancer cells compared with their drug-sensitive parental line. DNA Cell Biol 2011; 30(6): 413-18
45. Nourbakhsh M, Jaafari MR, Lage H, Abnous K. Nanolipoparticlesmediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iran J Basic Med Sci 2015; 18(4): 385
46. Kasaian J, Mosaffa F, Behravan J, Masullo M, Piacente S, Iranshahi M. Modulation of multidrug resistance protein 2 efflux in the cisplatin resistance human ovarian carcinoma cells A2780/RCIS by sesquiterpene coumarins. Phytother Res 2016; 30(1): 84-9
47. Cascorbi I, Haenisch S. Pharmacogenetics of ATP-binding cassette transporters and clinical implications In: Zhou J. Ed. Multi-Drug Resistance in Cancer. New York: 1nded 2010; pp. 95-121
48. Brown CM, Reisfeld B, Mayeno AN. Cytochromes P450: a structure-based summary ofbiotransformations using representative substrates. Drug Metab Rev 2008; 40: 1-100
49. Iyanagi T. Molecular mechanism of phase I and phase II drugmetabolizing enzymes: implications for detoxification. Int Rev Cytol 2007; 260: 35-112
50. Sarkaria JN, Kitange GJ, James CD et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14: 2900-8
51. Hakem R. DNA-damage repair; the good, the bad, and the ugly. EMBO J 2008; 27: 589-605
52. Stephen J. Elledge. “Cell cycle checkpoints: preventing an identity crisis”. Science 1996; 274 (5293): 1664-72
53. Ashwell S, Zabludoff S. DNA damage detection and repair pathways-recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008; 14: 4032-7
54. Morgan, David O. “Cyclin-Dependent Kinase: Engines, Clocks, and Microprocessors.” Annu Rev Cell Dev Biol 1997; 13: 261-91
55. Kilker RL, Hartl MW, Rutherford TM and Planas-Silva MD: Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. J Steroid Biochem Mol Biol 2004; 92: 63-71
56. Rudas M, Lehnert M, Huynh A, et al. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res 2008; 14: 1767-74
57. Stendahl M, Kronblad A, Rydén L, Emdin S, Bengtsson NO, Landberg G. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90: 1942-8
58. Hui R, Finney GL, Carroll JS, Lee CS, Musgrove EA and Sutherland RL: Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res 2002; 62: 6916-23
59. Rodriguez-Nieto S, Zhivotovsky B. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des 2006; 12: 4411-25
60. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70
61. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8
62. Yoshimoto N, Toyama T, Takahashi S, et al. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. Breast Cancer Res Treat 2011; 130(1): 331-9
63. Zhang L, Huang J, Yang N, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006; 103: 9136-41
64. Tchernitsa O, Kasajima A, Schäfer R, et al. Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol 2010; 222: 310-9
65. Ng EK, Wong CL, Ma ES, Kwong A. MicroRNAs as new players for diagnosis, prognosis, and therapeutic targets in breast cancer. J Oncol 2009; 2009: 305420
66. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffinembedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007; 7(1): 1
67. Rodrigues AC, Li X, Radecki L, et al. MicroRNA expression is differentially altered byxenobiotic drugs in different human cell lines. Biopharm Drug Dispos 2011; 32: 355-67
68. Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152-9
69. Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123: 372-9
70. Chen F, Zhu H-H, Zhou L-F, Wu S-S, Wang J, Chen Z. Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 2010; 23(5): 1457-62
71. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435(7043): 834-8
72. Egeland NG, Lunde S, Jonsdottir K, et al. The role of microRNAs as predictors of response to tamoxifen treatment in breast cancer patients. Int J Mol Sci 2015; 16(10): 24243-75
73. Ferracin M, Lupini L. MicroRNA expression profiling and its clinical impact in breast cancer. In: Babashah S, Ed. MicroRNAs: Key Regulators of Oncogenesis. Switzerland: Springer International Publishing 2014; pp. 355-67
74. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 283: 29897-903
75. Zhao R, Wu J, Jia W, et al. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 2011; 34: 675-80
76. Zhang R, Pang B, Xin T, et al. Plasma miR-221/222 family as novel descriptive and prognostic biomarkers for glioma. Mol neurobiol 2016; 53: 1452-60
77. Galardi S, Mercatelli N, Giorda E, et al. miR-221 and miR-222 expression affects the proliferation potentialof human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007; 282: 23716-24
78. Zhang C, Zhang J, Zhang A, et al. PUMA is a novel target of miR221/222 in human epithelial cancers. Int J Oncol 2010; 37(6): 1621-6
79. Falkenberg N, Anastasov N, Rappl K, et al. MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. Br J Cancer 2013; 109: 2714-23
80. Falkenberg N, Anastasov N, Rappl K, et al. MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. Br J Cancer 2013; 109(10): 2714-23
81. Felicetti F, Errico MC, Segnalini P, et al. MicroRNA-221and -222 pathway controls melanoma progression. Expert Rev Anticancer Ther 2008; 8: 1759-65
82. le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007; 26: 3699-708
83. Tang J, Ahmad A, Sarkar FH. The role of MicroRNAs in breast cancer migration, invasion and metastasis. Int J MolSci 2012; 13: 13414-37
84. Sherr CJ and Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12
85. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 2000; 97: 9042-6
86. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclindependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78(1): 59-66
87. Olashaw N, Pledger WJ. Paradigms of growth control: relation to Cdk activation. Sci Signal 2002; (134): RE7
88. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003; 13(2): 65-70
89. Viedma-Rodríguez R, Baiza-Gutman L, Salamanca Gómez F, et al. Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review). Oncol Rep 2014; 32(1): 3-15
90. Pohl G, Rudas M, Dietze O, et al. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J ClinOncol 2003; 21: 3594-600
91. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008; 10: e19
92. Matsuoka S, Edwards MC, Bai C, et al. “p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene”. Genes Dev 1995; 9 (6): 650-62
93. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001; 276: 36869-72
94. Manavalan TT, Teng Y, Appana SN, et al. Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. Cancer Lett 2011; 313(1): 26-43
95. Zhao J, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008; 283(45): 31079-86
96. García-Becerra R, Santos N, Díaz L, Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 2012; 14(1): 108-45
97. Giacinti L, Claudio PP, Lopez M, Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 2006; 11: 1-8
98. Gan R, Yang Y, Yang X, Zhao L, Lu J, Meng QH. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther 2014; 21(7): 290-6
99. Howe EN, Cochrane DR, Richer JK. The miR-200 and miR221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia 2012; 17: 65-77
100. Cruz-Munoz W, Khokha R.The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008; 45(3): 291-338
101. Lu Y, Roy S, Nuovo G, et al. Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenograftsin mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 2011; 286(49): 42292-302
102. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24(50): 7410-25
103. Terasaka K, Ichimura A, Sato F, Shimizu K, Tsujimoto G. Sustained activation of ERK1/2 by NGF induces microRNA-221 and 222 in PC12 cells. FEBS J 2009; 276(12): 3269-76
104. Di Leva G, Gasparini P, Piovan C, et al. MicroRNA Cluster 221222 and estrogen receptor î±interactions in breast cancer. J Natl Cancer Inst 2010; 102(10): 706-21
105. Zhang C, Kang C, Wang P, et al. MicroRNA-221 and-222 regulate radiation sensitivity by targeting the PTEN pathway. Int J Radiat Oncol Biol Phys 2011; 80(1): 240-8
106. Zhong S, Li W, Chen Z, Xu J, Zhao J. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene 2013; 531(1): 8-14
107. Shi Y, Wang J, Chandarlapaty S, et al. “PTEN is a protein tyrosine phosphatase for IRS1”. Nat Struct Mol Biol 2014; 21 (6): 522-27
108. Stambolic V, Suzuki A, De La Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39
109. Stambolic V, MacPherson D, Sas D et al. Regulation of PTEN transcription by p53. Mol Cell 2001; 8(2): 317-25
110. Zhang C, Zhang J, Zhang A, et al. PUMA is a novel target of miR221/222 in human epithelial cancers. Int J Oncol 2010; 37(6): 1621-6
111. Chen L, Willis SN, Wei A, et al. Differentialtargeting of prosurvival Bcl-2 proteins by their BH3-onlyligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403
112. Wang R, Wang X, Li B, et al. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 2009; 117: 45-54
113. Taylor DD, Doellgast GJ. Quantitation of peroxidase-antibody binding to membrane fragments using column chromatography. Anal Biochem 1979; 98: 53-9
114. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mrnas and microRNAs is a novel mechanism of genetic exchange between cells Nat Cell Biol 2007; 9: 654-59
115. Chen WX, Zhong SL, Ji MH, et al. MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer. Tumour Biol 2014; 35: 2883-92
116. Zhao L, Liu W, Xiao J, Cao B. The role of exosomes and “exosomal shuttle microRNA” in tumorigenesis and drug resistance. Cancer Lett 2015; 356(2): 339-46
117. Wei Y, Lai X, Yu S, et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat 2014; 147(2): 423-31
118. Falkenberg N, Anastasov N, Rappl K, et al. MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. Br J Cancer 2013; 109(10): 2714-23
119. Garofalo M, Quintavalle C, Romano G, Croce C, Condorelli G. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 2012; 12(1): 27